Aliases & Classifications for Spasticity

MalaCards integrated aliases for Spasticity:

Name: Spasticity 50 28

Summaries for Spasticity

NINDS : 50 Spasticity is a condition in which there is an abnormal increase in muscle tone or stiffness of muscle, which might  interfere with movement, speech, or be associated with discomfort or pain.  Spasticity is usually caused by damage to nerve pathways within the brain or spinal cord that control muscle movement. It may occur in association with spinal cord injury, multiple sclerosis, cerebral palsy, stroke, brain or head trauma, amyotrophic lateral sclerosis, hereditary spastic paraplegias, and metabolic diseases such as adrenoleukodystrophy, phenylketonuria, and Krabbe disease. Symptoms may include hypertonicity (increased muscle tone), clonus (a series of rapid muscle contractions), exaggerated deep tendon reflexes, muscle spasms, scissoring (involuntary crossing of the legs), and fixed joints (contractures). The degree of spasticity varies from mild muscle stiffness to severe, painful, and uncontrollable muscle spasms. Spasticity can interfere with rehabilitation in patients with certain disorders, and often interferes with daily activities.

MalaCards based summary : Spasticity is related to spastic paraplegia 30, autosomal recessive and spastic paraplegia 7, autosomal recessive. An important gene associated with Spasticity is DARS (Aspartyl-TRNA Synthetase). The drugs Dopamine and Baclofen have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, brain and t cells.

Wikipedia : 72 Spasticity (from Greek spasmos-, meaning \'drawing, pulling\') is a feature of altered skeletal muscle... more...

Related Diseases for Spasticity

Diseases related to Spasticity via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 801)
# Related Disease Score Top Affiliating Genes
1 spastic paraplegia 30, autosomal recessive 33.8 KIF1A WASHC5
2 spastic paraplegia 7, autosomal recessive 33.8 KIF1A SPG7
3 spastic paraplegia 15, autosomal recessive 33.8 SPG7 TECPR2
4 spastic paraplegia 20, autosomal recessive 33.8 KIF1A SPG7
5 spastic paraplegia 49, autosomal recessive 33.6 SPG7 TECPR2
6 spastic paraparesis 33.1 DDHD1 TECPR2
7 spastic ataxia 32.8 SACS SPG7
8 hereditary spastic paraplegia 32.6 CAPN1 DDHD1 KIF1A SACS SPG7 WASHC5
9 paraplegia 31.2 DDHD1 KIF1A SPG7 WASHC5
10 microcephaly 28.5 FAR1 PLAA SLC1A4 SLC2A1
11 spastic paraplegia 2, x-linked 12.4
12 spastic paraplegia 17, autosomal dominant 12.3
13 spastic paraplegia 11, autosomal recessive 12.3
14 spastic paraplegia 3, autosomal dominant 12.3
15 spastic paraplegia 23 12.3
16 spastic ataxia, charlevoix-saguenay type 12.3
17 spastic paraplegia 4, autosomal dominant 12.3
18 tropical spastic paraparesis 12.3
19 spastic paraplegia 9a, autosomal dominant 12.3
20 spastic paraplegia 54, autosomal recessive 12.3
21 spastic hemiplegia 12.3
22 spastic paraplegia 6, autosomal dominant 12.3
23 spastic paraplegia 10, autosomal dominant 12.3
24 spastic paraplegia 43, autosomal recessive 12.2
25 spastic paraplegia 8, autosomal dominant 12.2
26 spastic paraplegia 56, autosomal recessive 12.2
27 spastic paraplegia 5a, autosomal recessive 12.2
28 spastic diplegia 12.2
29 spastic paraplegia, optic atrophy, and neuropathy 12.2
30 spastic paraplegia 26, autosomal recessive 12.2
31 spastic paraplegia 48, autosomal recessive 12.2
32 spastic quadriplegia 12.2
33 spastic paraplegia 28, autosomal recessive 12.2
34 spastic paraplegia 45, autosomal recessive 12.2
35 spastic paraplegia 46, autosomal recessive 12.2
36 spastic paraplegia 57, autosomal recessive 12.2
37 spastic paraplegia 18, autosomal recessive 12.2
38 spastic paraplegia 55, autosomal recessive 12.2
39 spastic paraplegia 42, autosomal dominant 12.2
40 spastic paraplegia 31, autosomal dominant 12.2
41 spastic paraplegia 35, autosomal recessive 12.2
42 spastic paraplegia 13, autosomal dominant 12.2
43 spastic paraplegia 39, autosomal recessive 12.2
44 spastic paraplegia 72, autosomal recessive 12.2
45 spastic paraplegia 11 12.2
46 spastic paraplegia 47, autosomal recessive 12.2
47 spastic paraplegia 4 12.2
48 spastic paraplegia 12, autosomal dominant 12.1
49 spastic paraplegia 53, autosomal recessive 12.1
50 infantile-onset ascending hereditary spastic paralysis 12.1

Graphical network of the top 20 diseases related to Spasticity:



Diseases related to Spasticity

Symptoms & Phenotypes for Spasticity

Drugs & Therapeutics for Spasticity

Drugs for Spasticity (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 287)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
2
Baclofen Approved Phase 4,Phase 3,Phase 1,Phase 2 1134-47-0 2284
3
Levodopa Approved Phase 4 59-92-7 6047
4
Acetylcholine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 51-84-3 187
5
Memantine Approved, Investigational Phase 4 19982-08-2 4054
6
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1 2216-51-5 16666
7
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
8
Ethanol Approved Phase 4,Phase 3,Phase 2 64-17-5 702
9
Norepinephrine Approved Phase 4 51-41-2 439260
10
Clonidine Approved Phase 4,Phase 3,Phase 1,Phase 2 4205-90-7 2803
11 Piracetam Approved, Investigational Phase 4,Phase 2 7491-74-9
12
Dronabinol Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 1972-08-3 16078 2978
13
Lidocaine Approved, Vet_approved Phase 4,Phase 2 137-58-6 3676
14
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
15
Tizanidine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 51322-75-9 5487
16 Peppermint oil Approved, Investigational Phase 4,Phase 3
17
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
18
Peppermint Approved, Nutraceutical Phase 4,Phase 3
19 Etiracetam Investigational Phase 4,Phase 2 33996-58-6
20 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
21 calcium channel blockers Phase 4,Phase 3
22 abobotulinumtoxinA Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
23 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
24 Adrenergic Agents Phase 4,Phase 3,Phase 1,Phase 2
25 Cholinergic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
26 GABA Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Neuromuscular Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
28 Neuroprotective Agents Phase 4,Phase 3,Phase 2,Phase 1
29 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
30 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Neurotransmitter Uptake Inhibitors Phase 4,Phase 1
32 onabotulinumtoxinA Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
33 Dihydroxyphenylalanine Phase 4
34 Dopamine Agents Phase 4
35 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
36 Anticonvulsants Phase 4,Phase 3,Phase 1,Phase 2
37 Antidepressive Agents Phase 4,Phase 1,Phase 2
38 Antihypertensive Agents Phase 4,Phase 3,Phase 1,Phase 2
39 Excitatory Amino Acid Antagonists Phase 4,Phase 2
40 Excitatory Amino Acids Phase 4,Phase 2
41 incobotulinumtoxinA Phase 4,Phase 3,Phase 2
42 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
44 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
45 Antiparkinson Agents Phase 4,Phase 1
46 Botulinum Toxins Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
47 Botulinum Toxins, Type A Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
48 Carbidopa, levodopa drug combination Phase 4
49 Calcium, Dietary Phase 4,Phase 3,Phase 2
50
Serotonin Phase 4,Phase 1 50-67-9 5202

Interventional clinical trials:

(show top 50) (show all 666)

# Name Status NCT ID Phase Drugs
1 The Effectiveness of Early Botulinum Toxin A Injection for Lower Limbs Spasticity in Subacute Stroke Adults Unknown status NCT02505802 Phase 4 BoNT-A injection
2 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
3 Optimal Dose of Extracorporeal Shock Wave Therapy After Botulinum Toxin Type A Injection for Post-stroke Spasticity Unknown status NCT02358005 Phase 4
4 Upper Extremity Rehabilitation Using Robot and Botulinum Toxin Unknown status NCT02228863 Phase 4
5 Effects of Functional Electrical Stimulation on Gait in Children With Cerebral Palsy Unknown status NCT02462018 Phase 4
6 The Efficacy and Safety of MEDITOXIN® in Children With Cerebral Palsy Unknown status NCT01256021 Phase 4 Botulinum Toxin Type A
7 Rectus Femoris Tenotomy Versus Botulinum Toxin A for Stiff Knee Gait After Stroke Unknown status NCT02114736 Phase 4 Botulinum Toxin injection in the rectus femoris muscle
8 Does Oral Baclofen Improve Care and Comfort in Spastic Children in Nursing Homes? Unknown status NCT00752934 Phase 4 oral baclofen + placebo;placebo + oral baclofen
9 The Impact of Botulinum Toxin Treatment in Quality of Life of Cervical Dystonia Patients Unknown status NCT01664013 Phase 4 Nuronox
10 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4 L- DOPA;placebo
11 Functional Electrical Stimulation-Assisted Walking: Reduction of Secondary Complications Due to Spinal Cord Injury Unknown status NCT00201968 Phase 4
12 SISTERS: Spasticity In Stroke Study - Randomized Study Completed NCT01032239 Phase 4 intrathecal baclofen
13 Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients Completed NCT01968902 Phase 4
14 Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression Completed NCT02321436 Phase 4 BotulinumtoxinA;Placebo
15 Vanderbilt University Spasticity Management Program Evaluation Plan Completed NCT00179114 Phase 4 Botulinum Toxin Type A;Intrathecal baclofen administered by the Medtronic SyncroMed(TM) pump (ITB)
16 Asian Botulinum Clinical Trial Designed for Early Stroke Spasticity Completed NCT00234546 Phase 4 Botulinum toxin type A (Dysport®)
17 Effects of Botulinum Neurotoxin Type A (BoNT/A) Free of Complexing Proteins in the Spastic Equinovarus Foot Completed NCT03044080 Phase 4 IncobotulinumtoxinA;OnabotulinumtoxinA
18 BOTOX® Versus Zanaflex® for the Treatment of Post-Stroke or Traumatic Brain Injury Upper Limb Spasticity Completed NCT00430196 Phase 4 BOTOX®;Zanaflex®
19 Effects on Quality of Life Following Dysport Treatment in Post-Stroke Spasticity of the Arm Completed NCT00216411 Phase 4 Botulinum type A toxin (Dysport)
20 BOTOX® Economic Spasticity Trial (BEST) Completed NCT00549783 Phase 4
21 Memantine for Spasticity in MS Patients Completed NCT00638027 Phase 4 placebo;memantine
22 Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity Completed NCT00178646 Phase 4 Botox
23 A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients Completed NCT01964547 Phase 4 Sativex;Placebo
24 Spread And Effectiveness Of Botulinum Neurotoxin A In Spastic Equinus In Cerebral Palsy Completed NCT01276015 Phase 4 Botulinum Toxin Type A
25 Botulinum Toxin A Adult Gastrocnemius Muscle Study Completed NCT01278576 Phase 4 BOTOX-A®
26 SynchroMed II Post-Approval Study Completed NCT00773019 Phase 4
27 Recurrent Crying Spells in Cerebral Palsy Completed NCT01955655 Phase 4 Baclofen
28 Myobloc Atrophy Study Completed NCT02052024 Phase 4 Botox;MYOBLOC
29 Τhe Effectiveness of Hydrotherapy Exercises on the Rehabilitation of Hemiplegic Patients Completed NCT01460277 Phase 4
30 Levetiracetam in Chronic Neuropathic Pain Following Spinal Cord Injury Completed NCT00252954 Phase 4 Levetiracetam
31 Functional Effects of Botox on the Brain Using MRS and fMRI Completed NCT03373162 Phase 4 onabotulinumtoxinA
32 Tizanidine and Superficial Cervical Block on Pain After Thyroidectomy Completed NCT02725359 Phase 4 Placebo;Tizanidine;Bupivacaine;Saline
33 Investigating Botulinum Toxin A to Treat Acute Neck/Upper Shoulder Pain Following a New Spinal Cord Injury. Completed NCT00320281 Phase 4 botulinum toxin A
34 Effects of Botulinum Toxin Type A in Adults With Cerebral Palsy Completed NCT00432055 Phase 4 Botulinum toxin type A (Botox);placebo (saline)
35 Project to Improve Symptoms and Mood in People With Spinal Cord Injury Completed NCT00592384 Phase 4 venlafaxine XR;placebo
36 Post Marketing Surveillance Study of Dysport Completed NCT00210431 Phase 4
37 Study of the Effects on Motor Recovery of Early Post-stroke Spasticity Treatment Recruiting NCT02462317 Phase 4 botulinum A toxin;Baclofen;Placebo toxin;placebo baclofen
38 Intrathecal Baclofen (ITB) Delivery Location and Its Effect on Spasticity Recruiting NCT02903823 Phase 4 Baclofen bolus injection
39 The Effect of a Self-rehabilitation Program in Addition to Usual Treatment for Spasticity on Impairment and Activity Limitation in Patients With Spastic Hemiparesis Following Stroke Recruiting NCT02944929 Phase 4
40 The Movement of Botulinum Toxin Through the Lateral Gastrocnemius Muscle in Humans: An Expanded Examination Recruiting NCT03367429 Phase 4 Botox
41 Does Botulinum Toxin A Make Walking Easier in Children With Cerebral Palsy? Recruiting NCT02546999 Phase 4 botox;placebo
42 Treatment for Alcohol Dependence With Gabapentin Recruiting NCT02771925 Phase 4 Gabapentin 2g/day divided in two doses for 24 weeks;Placebo 2g/day divided in two doses for 24 weeks
43 Study to Evaluate Effects of DYSPORT® Injected in Lower and Upper Limb Combined With Guided Self-Rehabilitation Contract (GSC) Active, not recruiting NCT02969356 Phase 4 AbobotulinumtoxinA (Dysport®)
44 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Active, not recruiting NCT03226119 Phase 4
45 Meditoxin® Treatment in Patients With Post Stroke Upper Limb Spasticity Not yet recruiting NCT02757404 Phase 4
46 Imaging of 3D Innervation Zone Distribution in Spastic Muscles From High-density Surface EMG Recordings Not yet recruiting NCT03302741 Phase 4 Botulinum neurotoxin (BTX)
47 Randomised, Evaluation-blinded, Crossover, Controlled Study Assessing Dynamic Hand Splinting in Adults With Post-stroke Hemiplegia (Orthox) Not yet recruiting NCT02888548 Phase 4
48 Improvement After Botulinum Toxin Injections to the Arms in Children With Cerebral Palsy Terminated NCT00549471 Phase 4
49 Efficacy of Botulinum Toxin Versus Lidocaine in Treating Masticatory Myofascial Face Pain Using Ultrasound and EMG Guided Techniques Terminated NCT00992108 Phase 4 lidocaine;chemodenervation
50 Study of a New Generation Botulinum Toxin A2NTX to Treat Spasticity After Stroke Unknown status NCT01910363 Phase 2, Phase 3 A2NTX;BOTOX

Search NIH Clinical Center for Spasticity

Genetic Tests for Spasticity

Genetic tests related to Spasticity:

# Genetic test Affiliating Genes
1 Spasticity 28

Anatomical Context for Spasticity

MalaCards organs/tissues related to Spasticity:

38
Spinal Cord, Brain, T Cells, Testes, Bone, Skeletal Muscle, Cortex

Publications for Spasticity

Articles related to Spasticity:

(show top 50) (show all 3375)
# Title Authors Year
1
Quantitative Ultrasound Imaging to Assess the Biceps Brachii Muscle in Chronic Post-Stroke Spasticity: Preliminary Observation. ( 29398131 )
2018
2
Comments on "Transcutaneous electrical nerve stimulation improves walking capacity and reduces spasticity in stroke survivors: a systematic review and meta-analysis". ( 29376421 )
2018
3
The clinical assessment of spasticity in people with spinal cord damage: recommendations from the Ability Network, an international initiative. ( 29432722 )
2018
4
Ultrasound Strain Imaging to Assess the Biceps Brachii Muscle in Chronic Poststroke Spasticity. ( 29399851 )
2018
5
Relationship between radiographic patella-alta pathology and walking dysfunction in children with bilateral spastic Cerebral Palsy. ( 29149666 )
2018
6
Comparison of calf muscle architecture between Asian children with spastic cerebral palsy and typically developing peers. ( 29304114 )
2018
7
Towards flexible and tailored botulinum neurotoxin dosing regimens for focal dystonia and spasticity - Insights from recent studies. ( 29407165 )
2018
8
Spastic paraparesis and sensorineural hearing loss: keep brucellosis in mind. ( 29406895 )
2018
9
Reply: POLR3A variants in hereditary spastic paraplegia and ataxia. ( 29236946 )
2018
10
Evaluating the functional outcomes of ultrasound-guided botulinum toxin type A injections using the Euro-musculus approach for upper limb spasticity treatment in post-stroke patients; an observational study. ( 29422486 )
2018
11
Association of Early-Onset Spasticity and Risk for Cognitive Impairment With Mutations at Amino Acid 499 in SPAST. ( 29421991 )
2018
12
Differential changes in the spinal segmental locomotor output in Hereditary Spastic Paraplegia. ( 29353180 )
2018
13
Identification of a candidate enhancer for DMRT3 involved in spastic cerebral palsy pathogenesis. ( 29305858 )
2018
14
POLR3A variants in hereditary spastic paraplegia and ataxia. ( 29228109 )
2018
15
OnabotulinumtoxinA for the Treatment of Post-Stroke Distal Lower-Limb Spasticity: A Randomized Trial. ( 29330071 )
2018
16
Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy. ( 29423615 )
2018
17
Effects of treadmill training combined with serotonergic interventions on spasticity after contusive spinal cord injury. ( 29336209 )
2018
18
Neuroprotective effect of tanshinone IIA weakens spastic cerebral palsy through inflammation, p38MAPK and VEGF in neonatal rats. ( 29257210 )
2018
19
Assessment of Spasticity by a Pendulum Test in SCI Patients Who Exercise FES Cycling or Receive Only Conventional Therapy. ( 29324409 )
2018
20
Systematic review of systematic reviews for medical cannabinoids: Pain, nausea and vomiting, spasticity, and harms. ( 29449262 )
2018
21
Estimating medial gastrocnemius muscle volume in children with spastic cerebral palsy: a cross-sectional investigation. ( 29067675 )
2018
22
Homozygous<i>CAPN1</i>mutations causing a spastic-ataxia phenotype in 2 families. ( 29379883 )
2018
23
The Relationship Between Hand Function and Overlapping Motor Representations of the Hands in the Contralesional Hemisphere in Unilateral Spastic Cerebral Palsy. ( 29303031 )
2018
24
CYP2U1 activity is altered by missense mutations in hereditary spastic paraplegia 56. ( 29034544 )
2018
25
Changes in Tactile Function During Intensive Bimanual Training in Children With Unilateral Spastic Cerebral Palsy. ( 29433419 )
2018
26
Optimizing the management of spasticity in people with spinal cord damage: a clinical care pathway for assessment and treatment decision-making from the Ability Network, an international initiative. ( 29428347 )
2018
27
A hereditary spastic paraplegia-associated atlastin variant exhibits defective allosteric coupling in the catalytic core. ( 29180453 )
2018
28
Clinical and neuroimaging features of autosomal recessive spastic paraplegia 35 (SPG35): case reports, new mutations, and brief literature review. ( 29423566 )
2018
29
The experience of spasticity after spinal cord injury: perceived characteristics and impact on daily life. ( 29339776 )
2018
30
Subtle Imaging Findings Aid the Diagnosis of Adolescent Hereditary Spastic Paraplegia and Ataxia. ( 29379980 )
2018
31
Impact of spasticity on transfers and activities of daily living in individuals with spinal cord injury. ( 29334339 )
2018
32
Prosultiamine for treatment of lower urinary tract dysfunction accompanied by human T-lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis. ( 28965354 )
2018
33
Spastic paraparesis with basal ganglia changes: Infantile neuroaxonal dystrophy. ( 29323006 )
2018
34
Rewiring to Regain Function in Patients with Spastic Hemiplegia. ( 29261362 )
2018
35
Resting state fMRI studies in SPG4-linked hereditary spastic paraplegia. ( 29249364 )
2018
36
Intrathecal baclofen therapy versus conventional medical management for severe poststroke spasticity: results from a multicentre, randomised, controlled, open-label trial (SISTERS). ( 29326296 )
2018
37
Effectiveness of Faradic and Russian currents on plantar flexor muscle spasticity, ankle motor recovery, and functional gait in stroke patients. ( 29417699 )
2018
38
Identification of IFRD1 variant in a Han Chinese family with autosomal dominant hereditary spastic paraplegia associated with peripheral neuropathy and ataxia. ( 29362493 )
2018
39
Treatment with Botulinum Toxin for Refractory Fever Caused by Severe Spasticity: A Case Series. ( 29383493 )
2018
40
Role of Integrin Signaling Activation on the Development of Human T-Cell Leukemia VIrus-1 (HTLV-1)-Associated Myelopathy/Tropical Spastic Paraparesis: Its Relationship to HTLV-1-infected CD4+ T Cell Transmigrating Activity into the Tissues. ( 29400072 )
2018
41
The effect of HTLV-1 virulence factors (HBZ, Tax, proviral load), HLA class I and plasma neopterin on manifestation of HTLV-1 associated myelopathy tropical spastic paraparesis. ( 27845163 )
2017
42
Degeneration of serotonin neurons triggers spasticity in amyotrophic lateral sclerosis. ( 28856708 )
2017
43
Serial Casting as an Adjunct to Botulinum Toxin Type A Treatment in Children With Cerebral Palsy and Spastic Paraparesis With Scissoring of the Lower Extremities. ( 28393669 )
2017
44
Spasticity may obscure motor learning ability after stroke. ( 28904099 )
2017
45
PLA2G6 mutations associated with a continuous clinical spectrum from neuroaxonal dystrophy to hereditary spastic paraplegia. ( 28295203 )
2017
46
Long-term therapy with intrathecal baclofen improves quality of life in children with severe spastic cerebral palsy. ( 28237420 )
2017
47
A new phenotype associated with homozygous GRN mutations: complicated spastic paraplegia. ( 28000352 )
2017
48
A novel mutation in SLC25A46 causes optic atrophy and progressive limb spasticity, with no cerebellar atrophy or axonal neuropathy. ( 28369803 )
2017
49
Hereditary spastic paraplegia: More than an upper motor neuron disease. ( 28449883 )
2017
50
Stretch-reflex threshold modulation during active elbow movements in post-stroke survivors with spasticity. ( 28826019 )
2017

Variations for Spasticity

Expression for Spasticity

Search GEO for disease gene expression data for Spasticity.

Pathways for Spasticity

GO Terms for Spasticity

Cellular components related to Spasticity according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 axon cytoplasm GO:1904115 8.62 KIF1A SPG7

Biological processes related to Spasticity according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 anterograde axonal transport GO:0008089 8.62 KIF1A SPG7

Sources for Spasticity

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....